FOI release

Drug Testing Safeguards in Substance Misuse Services

Some or all of the information requested was not provided because we determined that the cost to do so would exceed the appropriate limit.

Case reference FOI2026/01405

Received 17 June 2026

Published 9 July 2026

Request

Freedom of Information Request — Drug Testing Safeguards in Substance Misuse Services

I am writing to make a request under the Freedom of Information Act 2000.

Please could you provide the following information:

1. Does your local authority currently provide substance misuse and/or addiction recovery services — whether delivered in-house, commissioned from external providers, or a combination of both?

If commissioned externally, please identify the provider(s) and the contract reference(s) where possible.

2. Whether services are delivered in-house or by an external provider, does the applicable drug and alcohol testing policy for staff working in those services include the following safeguards:

(a) Engagement of an independent Medical Review Officer (MRO) or equivalent qualified professional to review positive drug test results before any disciplinary action is taken;

(b) Obtaining an independent toxicological opinion when a positive result may be attributable to legal substances (such as over-the-counter CBD products, prescription medication, or dietary sources);

(c) Offering confirmatory re-testing or independent analysis following a disputed positive result;

(d) Referral to Occupational Health before disciplinary proceedings are initiated on the basis of a drug test result;

(e) Maintenance of a written drug and alcohol testing policy that meets the standards recommended by the ACAS guidance on managing drug and alcohol misuse at work?

If commissioned externally, please confirm whether these safeguards are specified in the commissioning contract or service specification, and provide the relevant clauses where possible.

3. Has your authority received any complaints, concerns, or whistleblowing disclosures from service users, staff, or members of the public regarding the drug testing practices of substance misuse service providers (or in-house services) in the last five years?

If so, how many and what was the general nature of those complaints?

4. Does your authority's contract monitoring or quality assurance process include any review of drug testing procedures or outcomes — whether delivered in-house or by a commissioned provider?

Additionally, I wish to raise the following in connection with the above request:

Peer-reviewed literature confirms that lawful, everyday substances can produce false positive results on immunoassay-based drug screening devices — the type of point-of-care test routinely used in workplace and service settings across the UK. Documented sources of cross-reactivity include poppy seeds, over-the-counter CBD products, prescribed medications (including codeine, tramadol, gabapentin, and certain antidepressants), tonic water, bananas, passive or environmental exposure to cannabis smoke, and certain antihistamines — among others.

In light of this, please also provide:

5. Is your authority (and/or its commissioned substance misuse service provider) aware of the cross-reactivity risks identified above?

Has any assessment been made of the likelihood of false positive results from lawful sources when using immunoassay screening?

6. Does the applicable drug and alcohol testing policy require that all positive screening results are confirmed by a second, independent analytical method — specifically GC-MS or LC-MS/MS — before any disciplinary, safeguarding, or service-access decision is made?

7. If confirmatory testing is not routinely carried out, on what basis are positive screening results treated as definitive?

8. Has your authority (and/or its provider) received any complaints, grievances, or representations from individuals who attributed a positive drug test result to any of the lawful sources listed above?

If so, how many in the last three years, and what was the outcome?

9. What guidance, if any, has been issued to staff involved in drug testing about the possibility of false positives from lawful substances, and the appropriate steps to take before acting on a screening result?

Response

Freedom of Information Request — Drug Testing Safeguards in Substance Misuse Services

I am writing to make a request under the Freedom of Information Act 2000.

Please could you provide the following information:

1. Does your local authority currently provide substance misuse and/or addiction recovery services — whether delivered in-house, commissioned from external providers, or a combination of both?

If commissioned externally, please identify the provider(s) and the contract reference(s) where possible.

2. Whether services are delivered in-house or by an external provider, does the applicable drug and alcohol testing policy for staff working in those services include the following safeguards:  

(a) Engagement of an independent Medical Review Officer (MRO) or equivalent qualified professional to review positive drug test results before any disciplinary action is taken;
  
(b) Obtaining an independent toxicological opinion when a positive result may be attributable to legal substances (such as over-the-counter CBD products, prescription medication, or dietary sources);
  
(c) Offering confirmatory re-testing or independent analysis following a disputed positive result;
  
(d) Referral to Occupational Health before disciplinary proceedings are initiated on the basis of a drug test result;
 
 (e) Maintenance of a written drug and alcohol testing policy that meets the standards recommended by the ACAS guidance on managing drug and alcohol misuse at work?
 
If commissioned externally, please confirm whether these safeguards are specified in the commissioning contract or service specification, and provide the relevant clauses where possible.

3. Has your authority received any complaints, concerns, or whistleblowing disclosures from service users, staff, or members of the public regarding the drug testing practices of substance misuse service providers (or in-house services) in the last five years?

If so, how many and what was the general nature of those complaints?


4. Does your authority's contract monitoring or quality assurance process include any review of drug testing procedures or outcomes — whether delivered in-house or by a commissioned provider?

Additionally, I wish to raise the following in connection with the above request:

Peer-reviewed literature confirms that lawful, everyday substances can produce false positive results on immunoassay-based drug screening devices — the type of point-of-care test routinely used in workplace and service settings across the UK. Documented sources of cross-reactivity include poppy seeds, over-the-counter CBD products, prescribed medications (including codeine, tramadol, gabapentin, and certain antidepressants), tonic water, bananas, passive or environmental exposure to cannabis smoke, and certain antihistamines — among others.

In light of this, please also provide:

5. Is your authority (and/or its commissioned substance misuse service provider) aware of the cross-reactivity risks identified above?

Has any assessment been made of the likelihood of false positive results from lawful sources when using immunoassay screening?

6. Does the applicable drug and alcohol testing policy require that all positive screening results are confirmed by a second, independent analytical method — specifically GC-MS or LC-MS/MS — before any disciplinary, safeguarding, or service-access decision is made?

7. If confirmatory testing is not routinely carried out, on what basis are positive screening results treated as definitive?

8. Has your authority (and/or its provider) received any complaints, grievances, or representations from individuals who attributed a positive drug test result to any of the lawful sources listed above?

If so, how many in the last three years, and what was the outcome?

9. What guidance, if any, has been issued to staff involved in drug testing about the possibility of false positives from lawful substances, and the appropriate steps to take before acting on a screening result?

Answer: The information for question 3 is not held in a form that would enable it to be located, retrieved and extracted within the Appropriate Time Limit which equates to 18 hours as defined by the Freedom of Information and Data Protection (Appropriate Limits and Fees) Regulations 2004.

 

Our electronic reporting systems are unable to run a report for this information. To ascertain the data requested, officers would need to manually check individual files for this information. An initial search has shown that 389 files would need to be checked for this information, and it is estimated that it would take 5 minutes to check each file. Once the details had been identified this would need to be noted and once all files had been checked in this way, the total figures requested could be calculated.

 

This would at a conservative estimate take at least 32 hours to complete. Where the Limit is exceeded Public Authorities are not obliged to supply the information requested by virtue of S12 of the Act. Please take this letter as a refusal notice under S17 of the Act.

 

However, within the 18 hour limit, we can provide answers for all other questions as requested. Please advise us if this is something you require.

Documents

There are no documents for this release.

This is Herefordshire Council's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.